EMAIL THIS PAGE TO A FRIEND

British journal of cancer

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients.


PMID 26057448

Abstract

Malignant pleural mesothelioma (MPM) is a rare and essentially incurable malignancy most often linked with occupational exposure to asbestos fibres. In common with other malignancies, the development and progression of MPM is associated with extensive dysregulation of cell cycle checkpoint proteins that modulate cell proliferation, apoptosis, DNA repair and senescence. The expression of cyclin-dependent kinase inhibitor p16/INK4A was evaluated by immunohistochemistry using tumour biopsy specimens from 88 MPM cases and a semi-quantitative score for p16/INK4A expression was obtained. Post-diagnosis survival and the survival benefit of chemotherapeutic intervention was correlated with p16/INK4A expression. A low, intermediate and high score for p16/INK4A expression was observed for 45 (51.1%), 28 (31.8%) and 15 (17.1%) of the MPM cases, respectively. Those cases with intermediate or high p16/INK4A tumour expression had a significantly better post-diagnosis survival than those cases whose tumours lost p16 expression (log-rank P<0.001). Those patients with sustained p16/INK4A expression who received chemotherapy also had a better survival than those treated patients whose tumours had lost p16/INK4A expression (log-rank P<0.001). Sustained p16/INK4A expression predicts better post-diagnosis survival in MPM and also better survival following chemotherapeutic intervention.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

GW21185 Anti-CDKN2A antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
SAB2502016
Anti-Cdkn2a antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB2501929
Anti-CDKN2A antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1306566
ANTI-P16INK4A (C-TERM E119) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA006628
Anti-RBM14 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV40635
Anti-RBM14 antibody produced in rabbit, affinity isolated antibody
AV37269
Anti-RBM14 antibody produced in rabbit, IgG fraction of antiserum
P9346
Liquified Phenol, meets USP testing specifications, ≥89.0%
C6H6O
SAB5300498
Monoclonal Anti-CDKN2A antibody produced in mouse, clone 1E12E10, ascites fluid
SAB5300499
Monoclonal Anti-CDKN2A antibody produced in mouse, clone 5A8A4, ascites fluid
SAB1404825
Monoclonal Anti-RBM14 antibody produced in mouse, clone 4E1, ascites fluid
P1037
Phenol, for molecular biology
C6H6O
P5566
Phenol, BioXtra, ≥99.5% (GC)
C6H6O
328111
Phenol, unstabilized, purified by redistillation, ≥99%
C6H6O
242322
Phenol, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, ≥99.0%
C6H6O
185450
Phenol, unstabilized, ReagentPlus®, ≥99%
C6H6O
77607
Phenol, BioUltra, for molecular biology, TE-saturated, ~73% (T)
C6H6O
33517
Phenol, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
C6H6O
16016
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC), crystalline (detached)
C6H6O
16017
Phenol, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
C6H6O
16018
Phenol, ≥96.0% (calc. on dry substance, T)
C6H6O
W322318
Phenol, ≥99%
C6H6O
W322340
Phenol, natural, 97%, FG
C6H6O
P4557
Phenol solution, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, for molecular biology
C6H6O
P4682
Phenol solution, Saturated with 0.1 M citrate buffer, pH 4.3 ± 0.2, BioReagent, for molecular biology
C6H6O
PLA0178
Rabbit anti-p16INK4a Antibody, Affinity Purified, Powered by Bethyl Laboratories, Inc.